LUMASON
Total Payments
$354,487
Transactions
83
Doctors
32
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $26,244 | 26 | 23 |
| 2018 | $195,689 | 35 | 9 |
| 2017 | $132,555 | 22 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $325,112 | 53 | 91.7% |
| Consulting Fee | $25,000 | 1 | 7.1% |
| Honoraria | $2,500 | 1 | 0.7% |
| Food and Beverage | $1,261 | 26 | 0.4% |
| Travel and Lodging | $613.82 | 2 | 0.2% |
Payments by Type
Research
$325,112
53 transactions
General
$29,375
30 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress Echocardiography with Dobutamine for the Diagnosis of Coronary Artery Disease | BRACCO DIAGNOSTICS INC. | $120,328 | 6 |
| A PROSPECTIVE MULTICENTER PHASE III CLINICAL EVALUATION OF THE SAFETY AND EFFICACY OF LUMASON/SONOVUE IN SUBJECTS UNDERGOING PHARMACOLOGIC STRESS ECHOCARDIOGRAPHY WITH DOBUTAMINE FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE | BRACCO DIAGNOSTICS INC. | $115,405 | 1 |
| A Prospective Multicenter Cohort Study Evaluating The Long Term Retention of Gadolinium In Human Bone and Skin After The Retrospective Administration of Multihance or Prohance in Comparison With a Control Group Receiving No Exposure to Gadolinium | BRACCO DIAGNOSTICS INC. | $34,442 | 0 |
| A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason/SonoVue | BRACCO DIAGNOSTICS INC. | $19,250 | 0 |
| A Parallel-Goup Comparison Of Two Doses Of MultiHance (0.10 mmol/kg And 0.05 mmol/kg) When Used For Magnetic Resonance Imaging (MRI) Of The Central Nervous System (CNS) | BRACCO DIAGNOSTICS INC. | $15,000 | 1 |
| LYSHCHIK_CONTRAST ENHANCED ULTRASOUND EVALUATION OF FOCAL LIVER LESIONS IN PATIENTS WITH CIRRHOSIS OR OTHER RISK FACTORS FOR DEVELOPING HCC | BRACCO DIAGNOSTICS INC. | $9,050 | 0 |
| TWEET_(HAYES)_SPONTANEOUS CORONARY ARTERY DISSECTION (SCAD): UTILITY OF ECHOCARDIOGRAPHY INCLUDING CONTRAST AND STRAIN IMAGING | BRACCO DIAGNOSTICS INC. | $7,038 | 0 |
| A Multicenter Clinical Evaluation of Safety and Efficacy of SonoVue as a Contrast Agent in Pediatric Echocardiography | BRACCO DIAGNOSTICS INC. | $2,500 | 1 |
| A PROSPECTIVE MULTICENTER PHASE III CLINICAL EVALUATION OF THE SAFETY AND EFFICACY OF LUMASON/SONOVUE | BRACCO DIAGNOSTICS INC. | $2,100 | 0 |
Top Doctors Receiving Payments for LUMASON — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Cardiovascular Disease | Saginaw, MI | $17.83 | 1 |
| , M.D | Cardiovascular Disease | Rowlett, TX | $15.75 | 1 |
| , MD | Diagnostic Radiology | Fruita, CO | $15.19 | 1 |
| , DO | Interventional Cardiology | Chicago, IL | $14.19 | 1 |
| , MD | Cardiovascular Disease | Salina, KS | $13.24 | 1 |
| , MD | Cardiovascular Disease | Decatur, IL | $9.55 | 1 |
| , MD | Cardiovascular Disease | Decatur, IL | $9.55 | 1 |
| , M.D | Cardiovascular Disease | Decatur, IL | $9.54 | 1 |
Ad
Manufacturing Companies
- BRACCO DIAGNOSTICS INC. $354,487
Product Information
- Type Drug
- Total Payments $354,487
- Total Doctors 32
- Transactions 83
About LUMASON
LUMASON is a drug associated with $354,487 in payments to 32 healthcare providers, recorded across 83 transactions in the CMS Open Payments database. The primary manufacturer is BRACCO DIAGNOSTICS INC..
Payment data is available from 2017 to 2019. In 2019, $26,244 was paid across 26 transactions to 23 doctors.
The most common payment nature for LUMASON is "Unspecified" ($325,112, 91.7% of total).
LUMASON is associated with 9 research studies, including "A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress Echocardiography with Dobutamine for the Diagnosis of Coronary Artery Disease" ($120,328).